Citations

Clear

2303 citation(s) found for "Yu, Edward".

Staged Resection of Difficult-to-Treat Intracranial Meningiomas: A Systematic Review of the Indications, Surgical Approaches, and Postoperative Outcomes
Kuo, Cathleen C. , Patel, Neal , Brown, Nolan J. , Pennington, Zach , Bui, Nicholas, Reardon, Taylor , Hsu, Frank P. K. , Mohyeldin, Ahmed, Pennington, Zach , Gendreau, Julian , Lien, Brian V. , Prevedello, Daniel M. , Kuan, Edward C

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | January 19, 2023 | Volume: 85 | Issue: 02 | Pages: 131-144

10.1055/a-2015-8238 | PMID 38449578 Get It

Abstract Introduction Meningiomas—the most common extra-axial tumors—are benign, slow-growing dural-based lesions that can involve multiple cranial fossae and can progress insidiously for years until coming to clinical attention secondary to compression of adjacent neurovascular structures. For complex, multicompartmental lesions, multistaged surgeries have been increasingly shown to enhance maximal safe resection while minimizing adverse sequela. Here, we systematically review the extant literature to highlight the merits of staged resection. Methods PubMed, Scopus, and Web of Science databases were queried to identify articles reporting resections of intracranial meningiomas using a multistaged approach, and articles were screened for possible inclusion in a systematic process performed by two authors. Results Of 118 identified studies, 36 describing 169 patients (mean age 42.6 ± 21.3 years) met inclusion/exclusion criteria. Petroclival lesions comprised 57% of cases, with the most common indications for a multistaged approach being large size, close approximation of critical neurovascular structures, minimization of brain retraction, identification and ligation of deep vessels feeding the tumor, and resection of residual tumor found on postoperative imaging. Most second-stage surgeries occurred within 3 months of the index surgery. Few complications were reported and multistaged resections appeared to be well tolerated overall. Conclusions Current literature suggests multistaged approaches for meningioma resection are well-tolerated. However, there is insufficient comparative evidence to draw definitive conclusions about its advantages over an unstaged approach. There are similarly insufficient data to generate an evidence-based decision-making framework for when a staged approach should be employed. This highlights the need for collaborative efforts among skull base surgeons to establish an evidentiary to support the use of staged approaches and to outline those indications that merit such an approach.
The Effects of Palovarotene in Patients with Fibrodysplasia Ossificans Progressiva: A Plain Language Summary
Pignolo, Robert J. , Mukaddam, Mona Al , Berglund, Staffan K. , Cheung, Angela M. , Cunto, Carmen De , Delai, Patricia , Haga, Nobuhiko , Mancilla, Edna E. , Marino, Rose , Strahs, Andrew, Cheung, Angela M , Hsiao, Edward C. , Baujat, Geneviève , Brown, Matthew , Kannus, Pekka , Keen, Richard , Sang, Kim‐Hanh Le Quan , Kaplan, Frederick S.

Mayo Clinic

Future Rare Diseases | January 18, 2023 | Volume: 3 | Issue: 1 | Pages: No page available

10.2217/frd-2022-0015 Get It

Induction and Maintenance Treatment With Upadacitinib Improves Health-Related Quality of Life in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 Study Results
Panés, Julián , Loftus, Edward V. , Higgins, Peter , Yao, Xuan , Ilo, Dapo, Phillips, Charles M., Tran, Jacinda , González, Yuri Sánchez , Vermeire, Séverine , Loftus, Edward V , Panes, Julian , Vermeire, Séverine , Lindsay, James Oliver , Zhou, Wen

Mayo Clinic

Inflammatory Bowel Diseases | January 16, 2023 | Volume: 29 | Issue: 9 | Pages: 1421-1430

10.1093/ibd/izac260 | PMID 36645051 Get It

Abstract Background We evaluated the health-related quality of life (HRQoL) benefits of upadacitinib (UPA) induction and maintenance treatment in a phase 3 study of patients with ulcerative colitis (UC) across a broad range of patient-centered outcomes. Methods Patients received UPA 45 mg once daily or placebo as induction treatment for 8 weeks. Patients who achieved clinical response were rerandomized to receive once daily UPA 15 mg, 30 mg, or placebo as maintenance treatment for 52 weeks. The percentages of patients reporting a clinically meaningful within-person change from baseline in the Ulcerative Colitis Symptoms Questionnaire, Inflammatory Bowel Disease Questionnaire, Work Productivity and Impairment Questionnaire, 36-Item Short Form Survey, and European Quality of Life-5 Dimension 5 Levels were evaluated at weeks 2 and 8 of induction and at weeks 0 and 52 of maintenance. Results Significant improvements from baseline in all HRQoL measures except the Work Productivity and Impairment Questionnaire–absenteeism were achieved with UPA (P < .001) vs placebo as early as week 2 of induction. These improvements were sustained at week 52 with significantly more patients treated with either 15 mg or 30 mg UPA vs placebo achieving meaningful within-person change in the Ulcerative Colitis Symptoms Questionnaire; Inflammatory Bowel Disease Questionnaire; overall work impairment, presenteeism, and activity impairment; both 36-Item Short Form Survey Physical and Mental Component Summaries; and European Quality of Life-5 Dimension 5 Levels (P < .001). Conclusions Induction treatment with UPA 45 mg significantly improved HRQoL measures. A significantly higher percentage of patients who responded to induction treatment with UPA maintained clinically meaningful improvements consistently across a wide range of HRQoL outcomes after 52 weeks of maintenance therapy with UPA (15 mg and 30 mg) compared with placebo. (ClinicalTrials.gov, Numbers: NCT02819635, NCT03653026).
Abstract P056: Germline cancer susceptibility gene testing in unselected patients with soft tissue sarcoma: a multi-center prospective study
Ailts, Isaak , Golafshar, Michael A. , Klint, Margaret, Barrus, Kathleen , Nussbaum, Samuel R., Leach, Brandie, Young, Sarah , Samadder, N. Jewel , Seetharam, ­Mahesh , Golafshar, Michael , Kunze, Katie L. , Esplin, Edward D. , Leach, Brandie

Mayo Clinic

Cancer Prevention Research | January 4, 2023 | Volume: 16 | Issue: 1_Supplement | Pages: P056-P056

10.1158/1940-6215.precprev22-p056 Get It

Abstract Sarcomas are rare heterogenous mesenchymal tumors with over 75 different subtypes, with varying biology and outcomes, with no clear inciting factor in the vast majority. The germline genetic susceptibility to sarcoma is not very well characterized. Identification of any underlying germline predisposition can have important implications for treatment of patients and screening recommendations for family members. To determine the prevalence of pathogenic germline variants (PGV) in patients with sarcomas, we undertook the Interrogating Cancer Etiology Using Proactive Genetic Testing (INTERCEPT) study, a prospective multi-site study of germline sequencing using a >80-gene next-generation sequencing platform. The study was done at the three Mayo Clinic Cancer Centers between April 1, 2018, and March 31, 2020. Patients were not selected based on stage, family cancer history, ethnicity, or age. Family cascade testing was offered at no charge. Results: 115 adult patients with soft tissue sarcoma were included in the study. The median age was 60 years, 58.5% were male, 81% were White. The anatomical location of the primary tumor included extremities (33.0%), retroperitoneum (18.2%), trunk (12.2%), head and neck (7.8%). Family history of cancer was present in 63% of the study population. Ten patients (8.7%) had a PGV. Thirty percent of the patients with PGV had stage IV sarcoma (3/10), and 70% (7/10) had earlier stage sarcoma (stages I-III). Among patients who were found to have a variant of uncertain significance (VUS), 40% (22/55) had stage IV sarcoma and 60% (33/55) had earlier stage disease. Of the 10 patients with PGV, high to medium penetrance gene abnormalities were identified in 8 patients (80%) involving TP53 (3), BRCA1 (1), SDHA (1), ATM (2) and heterozygous deletion of NBN (1) genes. Of these PGV, gene deletions were observed in 6/10 while missense variants comprised the remaining 4. The vast majority of the PGV (70%) would not have been identified using the current guidelines utilizing the 2018 or 2020 National Comprehensive Cancer Network (NCCN), National Society of Genetic Counselors (NSGC) or American College of Medical Genetics and Genomics. Conclusion: In this prospective, multi-site study comprising over 100 patients with diverse sarcomas, unselected germline testing identified a PGV in 1 in 11 patients (8.7%) with the majority of these not being detected using current standard of care guidelines for genetic testing. Because of the rarity of sarcomas, in addition to limited effective treatment options for advanced disease, large scale germline testing in sarcomas represents a potentially impactful strategy to assess therapeutic options and for assessment of familial risk. Citation Format: Isaak Ailts, Michael A. Golafshar, Katie L. Kunze, Margaret Klint, Kathleen Barrus, Samuel Nussbaum, Edward Esplin, Brandie Leach, Sarah Young, Niloy Jewel Samadder, Mahesh Seetharam. Germline cancer susceptibility gene testing in unselected patients with soft tissue sarcoma: a multi-center prospective study. [abstract]. In: Proceedings of the AACR Special Conference: Precision Prevention, Early Detection, and Interception of Cancer; 2022 Nov 17-19; Austin, TX. Philadelphia (PA): AACR; Can Prev Res 2023;16(1 Suppl): Abstract nr P056.
Structure-Based Identification of Natural-Product-Derived Compounds with Potential to Inhibit HIV-1 Entry
Ugwu-Korie, Nneka, Quaye, Osbourne , Wright, Edward , Languon, Sylvester , Agyapong, Odame , Broni, Emmanuel , Gupta, Yash , Kwofie, Samuel K., Kwofie, Samuel K , Gupta, Yash , Kempaiah, Prakasha

Mayo Clinic

Molecules | January 4, 2023 | Volume: 28 | Issue: 2 | Pages: 474

10.3390/molecules28020474 | PMID 36677538 Get It

Broadly neutralizing antibodies (bNAbs) are potent in neutralizing a wide range of HIV strains. VRC01 is a CD4-binding-site (CD4-bs) class of bNAbs that binds to the conserved CD4-binding region of HIV-1 envelope (env) protein. Natural products that mimic VRC01 bNAbs by interacting with the conserved CD4-binding regions may serve as a new generation of HIV-1 entry inhibitors by being broadly reactive and potently neutralizing. This study aimed to identify compounds that mimic VRC01 by interacting with the CD4-bs of HIV-1 gp120 and thereby inhibiting viral entry into target cells. Libraries of purchasable natural products were virtually screened against clade A/E recombinant 93TH057 (PDB: 3NGB) and clade B (PDB ID: 3J70) HIV-1 env protein. Protein–ligand interaction profiling from molecular docking and dynamics simulations showed that the compounds had intermolecular hydrogen and hydrophobic interactions with conserved amino acid residues on the CD4-binding site of recombinant clade A/E and clade B HIV-1 gp120. Four potential lead compounds, NP-005114, NP-008297, NP-007422, and NP-007382, were used for cell-based antiviral infectivity inhibition assay using clade B (HXB2) env pseudotype virus (PV). The four compounds inhibited the entry of HIV HXB2 pseudotype viruses into target cells at 50% inhibitory concentrations (IC50) of 15.2 µM (9.7 µg/mL), 10.1 µM (7.5 µg/mL), 16.2 µM (12.7 µg/mL), and 21.6 µM (12.9 µg/mL), respectively. The interaction of these compounds with critical residues of the CD4-binding site of more than one clade of HIV gp120 and inhibition of HIV-1 entry into the target cell demonstrate the possibility of a new class of HIV entry inhibitors.
Alcohol abstinence partially restores peripheral mucosal-associated invariant T cells in patients with alcoholic hepatitis
Li, Wei , Lin, Edward L. , Liangpunsakul, Suthat , Rane, Susimita, Chalasani, Sai, Puri, Puneet , Kamath, Patrick S. , Shah, Vijay H. , Katz, Barry P., Radaeva, Svetlana , Crabb, David W. , Chalasani, Naga , Yu, Qigui, Lin, Edward, Lan, Jie , Sanyal, Arun J. , Yu, Qigui

Mayo Clinic

The Journal of Immunology | January 2, 2023 | Volume: 200 | Issue: Supplement_1 | Pages: 166.64-166.64

10.4049/jimmunol.200.supp.166.64 Get It

Abstract Alcoholic hepatitis (AH) develops in a small percentage of heavy drinkers. The adaptive immune system of AH patients is hyper-activated, yet dysregulated and ineffective against infectious diseases. Mucosal-associated invariant T (MAIT) cells are innate-like lymphocytes that are found in liver, intestinal mucosa, and peripheral blood and contribute to protection against infectious diseases. To determine whether MAIT cells were dysregulated in heavy drinkers and the effect of alcohol abstinence on MAIT cell recovery, we compared peripheral MAIT cells between AH patients and heavy drinkers without liver disease (HDC) at baseline and 6- and 12-month followup. At baseline, AH patients had severely reduced frequency of MAIT cells than HDC and healthy donor controls (HC), whereas MAIT cell frequency was not significantly different between HDC and HC. In addition, MAIT cells in AH patients expressed higher levels of the activation markers (CD69, CD38, and HLA-DR) as well as the immune checkpoint inhibitor PD-1. Multiplex immunoassays showed that plasma levels of several cytokines related to MAIT cell activation were elevated in AH patients (IFN-s, IL-7, IL-15, IL-17, IL-18, and IL-23, and TNF-a). In AH patients, the frequency MAIT cells and CD38-expressing MAIT cells correlated with levels of several cytokines and AST. At followup, AH patients had increased MAIT cell frequency and decreased MAIT cell activation with cessation of alcohol. However, abstinent AH patients still had higher levels of CD38-expressing MAIT cells than HDC at 6-month followup. Conclusion Blood MAIT cells were severely reduced and were dysregulated in AH patients and alcohol abstinence partially reversed abnormalities in MAIT cell frequency and phenotype.
Transforming growth factor beta induced PD-L1 expression promotes pro-fibrotic signaling
Leof, Edward B. , Jung, Mi-Yeon, Kang, Jeong Han

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 204 | Issue: 1_Supplement | Pages: 79.8-79.8

10.4049/jimmunol.204.supp.79.8 Get It

Abstract Immune checkpoint proteins such as programmed death-ligand 1 (PD-L1) retain general immune homeostasis and self-tolerance. PD-L1 binds to programmed cell death protein 1 (PD-1) and inhibits T cell activation or protects tumor cells from T cell-mediated killing. PD-L1 has recently been shown to be up-regulated in invasive lung fibroblasts by p53 and focal adhesion kinase (FAK), any potential role of transforming growth factor-beta (TGFβ) in PD-L1 action is unknown in fibrosis. TGFβ is a mysterious protein with various roles in healthy tissue homeostasis/development as well as the development or progression of cancer, fibrotic disorders, and immune modulation, et al. In the current study, we showed that TGFβ induces the expression of the immunoinhibitory molecule PD-L1 in human and murine fibroblasts in a Smad2/3- and YAP/TAZ-dependent manner. Furthermore, PD-L1 knockdown decreased the TGFβ-dependent induction of extracellular matrix proteins, including collagen Ia1 (colIa1) and alpha-smooth muscle actin (α-SMA), and cell migration/wound healing. In addition to an endogenous role for PD-L1 in profibrotic TGFβ signaling, TGFβ stimulated-human lung fibroblast-derived PD-L1 into extracellular vesicles (EVs) capable of inhibiting T-cell proliferation in response to T cell receptor stimulation and mediating fibroblast cell migration. These findings provide new insights and potential targets for a variety of fibrotic and malignant diseases.
DNA-mediated transfer of major histocompatibility class II I-Ab and I-Abm12 genes into B lymphoma cells: molecular and functional analysis of introduced antigens.
Ben‐Nun, Avraham, McIntyre, Katherine, Leeman, Sara A., McKean, D J, Seidman, Jonathan G. , Glimcher, L H, Seidman, Jonathan G , Choi, Edward Man-Lik

Mayo Clinic

The Journal of Immunology | December 31, 2022 | Volume: 135 | Issue: 2 | Pages: 1456-1464

10.4049/jimmunol.135.2.1456 Get It

Abstract A20.2J B lymphoma cells have been co-transfected with the A alpha b, A beta b or with the A alpha b, A beta bm12 and neomycin resistance genes. The transfected cell lines constitutively express the I-Ab or I-Abm12 class II molecules at a level comparable with that of the endogenous I-Ad antigen. The I-Ab antigens expressed on three independently transfected B cell clones (A20.Ab.1, A20.Ab.2, and A20.Ab.3) are serologically and functionally indistinguishable from the I-Ab molecules expressed by control H-2bxd B hybridoma cells (LB cells). These transfected cell lines were potent I region-restricted antigen-presenting cells to a large panel of antigen-specific, autoreactive and alloreactive T cell hybridomas, as well as normal T cell clones. There were not significant differences in the efficiency of antigen presentation by the Ia molecules encoded by the transfected, as compared with the endogenous, I-A genes. The expression of a functional I-Ab antigen on the surface of cells transfected with A beta bm12 and A alpha b genes is consistent with previous work that implicated the A beta-chain alone in the bm 12 mutation. Furthermore, because the transfected A20.Ab and A20.Abm12 cells display the serologic and functional properties of normal spleen cells from the wild-type and mutant mouse strains, respectively, it is clear that class II genes do not undergo unexpected and unpredictable alterations after transfection in this system. This system permits us to investigate the structural requirements for interactions between class II major histocompatibility complex antigens, a foreign antigen, and the T cell receptor by in vitro site-directed mutagenesis coupled with DNA-mediated gene transfer.
I-Ak polymorphisms define a functionally dominant region for the presentation of hen egg lysozyme peptides.
Rosloniec, Edward F. , Vitez, L J, Beck, B N, Buerstedde, J M, McKean, D J, Landais, D, Benoist, Christophe, Mathis, D, Freed, J H, Beck, BN, Buerstedde, J M, McKean, D J, Landais, Didier, Benoist, Christophe O. , Mathis, Diane J.

Mayo Clinic

The Journal of Immunology | December 31, 2022 | Volume: 143 | Issue: 1 | Pages: 50-58

10.4049/jimmunol.143.1.50 Get It

Abstract The class II molecules of the MHC not only bind processed antigenic peptides but also interact with the TCR. This latter interaction is thought to be the basis for allele specific "restriction" of Ag presentation to T cells. The specificity of this interaction is likely due to amino acid differences in a small number of polymorphic or "hypervariable" regions located in the amino terminal domains of the alpha- and beta-chains. We have explored the functional significance of these polymorphic regions in an I-Ak-restricted, hen egg lysozyme specific Ag presentation system in which the measurement of IL-2 production by T cell hybridomas was used as the indicator of TCR recognition of the I-A/Ag complex. Chimeric I-A molecules, in which b allelic residues were substituted in one or more of the polymorphic regions of the A alpha k chain or in which d allelic residues were substituted in one or more of the polymorphic regions of the A beta k chain, were used to examine the contribution of each polymorphic region of the molecule to its function. The results obtained demonstrate that the regions between residues 69 to 76 of the A alpha k chain and the regions between residues 63 to 67 and 75 to 78 of the A beta k-chain exert a dominant effect on the presentation of lysozyme peptides by I-Ak to the T cell hybridomas in our panel. These observations were confirmed and extended by the analysis of Ag presentation by seven serologically selected mutants, all of which have amino acid interchanges in or around the dominant polymorphic regions. The results suggest that the serologically selected mutants fail to present Ag not because they fail to bind the peptide Ag but because the amino acid substitutions destabilize the interaction between the Ia/peptide complex and the TCR. Use of the recently published hypothetical model for class II structure to interpret the Ag presentation results suggests that the dominant polymorphic regions lie across from one another near one end of the alpha-helices that form the two walls of the proposed Ag-binding cleft located on the top surface of the class II molecule. Furthermore, the majority of the amino acids which have been changed in the serologically selected mutants have side chains which are postulated to point up toward the exterior of the molecule and would, therefore, be potential contact residues for the TCR.
Regulation of IkB α phosphorylation by PKC- and Ca2+-dependent signal transduction pathways
Steffan, N M, Bren, Gary D., Frantz, Betsy, Tocci, Michael J., O’Neill, Edward A., Paya, C. V.

Mayo Clinic

The Journal of Immunology | December 31, 2022 | Volume: 155 | Issue: 10 | Pages: 4685-4691

10.4049/jimmunol.155.10.4685 Get It

Abstract The Ca2+-dependent phosphatase calcineurin, a target of FK506 and CsA, synergizes with PKC-induced activation of nuclear factor (NF)-kappa B in T cell lines. We have investigated whether this synergy is present in other cell types and the mechanism(s) by which these two pathways lead to NF-kappa B activation. While this synergy is present in other cell types, in the monocytic cell line U937 calcineurin is also sufficient to activate NF-kappa B. Having previously shown that Ca2+- and PKC-dependent pathways synergize by accelerating the degradation of IkB α, we focused on the regulation of IkB α phosphorylation. While PKC-dependent pathways sequentially result in the phosphorylation and in an incomplete degradation of IkB α in T cell lines, co-activation of Ca2+-dependent pathways accelerates the rate of IkB α phosphorylation and results in its complete degradation. Activation of Ca2+-dependent pathways alone do not result in the phosphorylation and/or degradation of IkB α in Jurkat T or in U937 cells. Treatment of T cells with the selective PKC inhibitor GF109203X abrogates the PMA-induced IkB α phosphorylation/degradation irrespective of activation of Ca2+-dependent pathways, but not the phosphorylation and degradation of IkB α induced by TNF-α, a PKC-independent stimulus. Contrary to the interaction with PKC, Ca2+-dependent pathways synergize with TNF-α not at the level of IkB α phosphorylation, but at the level of its degradation. These results indicate that Ca2+-dependent pathways, including the phosphatase calcineurin, participate in the regulation of NF-kappa B in a cell specific fashion and synergize with PKC-dependent and -independent pathways at the level of IkB α phosphorylation and degradation.